Disease Burden of Overactive Bladder

Abstract

Overactive bladder (OAB) is characterised by the storage symptoms of urgency, with or without urge incontinence, and usually with urinary frequency and nocturia. OAB is a common condition that affects people of all ages within society. It has an estimated prevalence of 16% and is known to adversely affect quality of life (QOL). Assessment of the QOL of patients is important to understanding both the burden of disease and improvement after treatment. In clinical practice, the physician's assessment of the disease burden of OAB has been shown to be inaccurate and non-reproducible. Psychometrically robust self-completion questionnaires provide a valid, reproducible and rapid assessment of patient-reported disease impact that can elicit the impact of symptoms, and they are also useful for the evaluation of the efficacy of an intervention. Many different questionnaires have been developed to assess the QOL impact of OAB. Generic instruments measure very broad aspects of health and are suitable for a wide range of patient groups and general population screening. They can be applied to patients with any medical condition and provide a measure of morbidity but are less sensitive to clinically relevant change in conditions such as OAB. Condition-specific questionnaires offer greater sensitivity and responsiveness to change in the assessment of QOL of specific patient groups. Single-item global assessment questionnaires are useful in conditions such as OAB that have multiple and varied symptoms, and reflect an individual's needs, concerns and values. Patient-derived outcome measures are used in real-world clinical practice, clinical trials, health economic research and healthcare planning.

Diastereospecific Synthesis of Tetrahydroisoquinolines via Radical Cyclization: Application in the Synthesis of ent‐Tadalafil

“…It acts as a β 2 adrenoreceptor agonist and shows vasodilating activity [1] . Solifenacin, a M3 selective receptor blocker is used to treat urinary incontinence [2] . Naturally occurring alkaloid noscapine isolated from papaver somniferum plant is used as a cough‐suppressing medicine [3] .…”

Suivi et évaluation des traitements du syndrome clinique d’hyperactivité vésicale non neurologique

“…Ainsi, le calendrier mictionnel (mentionnant ou non le nombre de protections urinaires (8)) apparaît comme l'outil indispensable du suivi et d'évaluation du patient ayant un SCHV (9). En effet, la plupart des études définissent la réponse au traitement du SCHV comme étant une réduction de plus de 50% du nombre d'épisodes d'incontinence urinaire par urgenturie (7) ; d' autres proposent une réduction de 2 épisodes d'urgenturie par semaine (10), une réduction de 50% du poids des protections urinaires (11), ou encore 3 à 7 jours consécutifs de continence par semaine (12).…”

Characterizing the Health-Related Quality of Life Burden of Overactive Bladder Using Disease-Specific Patient-Reported Outcome Measures: A Systematic Literature Review

“…In terms of measure properties, the OAB-q consists of a validated eight-item symptom bother scale used to determine urinary frequency, nocturia, urgency and continence [13, 14]. It is the first instrument to include an evaluation of both incontinence and continence in OAB [13], and is therefore widely used because of the ability to generally assess patients with OAB. The OAB-q also includes a 25-item HRQoL scale rating performance in each of four subscales (coping, sleep, concern and social interaction).…”

“…The OAB-q also includes a 25-item HRQoL scale rating performance in each of four subscales (coping, sleep, concern and social interaction). Each item (including symptom bother items) is scored on a 6-point Likert scale ranging from 1 point (not at all) to 6 points (a very great deal) [13]. A symptom bother total score is derived from the eight-item symptom bother scores, then converted into a 0–100 scale on which higher scores signify greater symptom impact and lower scores signify improved symptom bother [15].…”